Skip to main content

MDS Closes $615M Molecular Devices Acquisition

NEW YORK (GenomeWeb News) — MDS today said it has closed its $615-million acquisition of Molecular Devices.
 
MDS is using the purchase to create a new segment, MDS Analytical Technologies, which is a hybrid of Molecular Devices and the MDS Sciex business.
 
MDS Sciex President Andy Boorn will lead the new business unit.
 
With the deal, Molecular Devices’ stock was delisted yesterday from the Nasdaq Global Select Market. 
 
The two businesses had combined revenues of $432 million last year, and MDS expects Molecular Devices to contribute $190 million in revenue over the coming year, the company said in January.
 
MDS said at the time that its Sciex business will continue its mass spectrometry partnerships with Applied Biosystems and PerkinElmer. 

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.